

## 12. Managing pharmacovigilance systems: optimising the rational use of new TB medicines and novel regimens

**THE 46<sup>TH</sup> UNION  
WORLD CONFERENCE  
ON LUNG HEALTH**

CAPE TOWN, SOUTH AFRICA  
2-6 DECEMBER 2015

Friday, 04 December 2015, 13:30 - 15:00

Room MR 2.64-2.66

Type of session	Symposium
Track	Advancing the End TB strategy and other policy issues
Description	In many countries notification about adverse reactions to anti-TB drugs is limited to spontaneous reporting. This level of pharmacovigilance (PV) is insufficient when the risk of adverse effects and harms related to the medicines is high, the treatment regimens are complicated, the experience with the use of certain medicines in specific populations is limited and when patients receive treatment with novel regimens and new drugs. This symposium describes approaches to improve TB patient safety through managing PV systems to gather more data on the long-term safety of TB regimens among populations in developing countries.
Target audience	<ol style="list-style-type: none"> <li>1. Physicians, nurses, pharmacists, MDR-TB health care providers</li> <li>2. Health programme managers, policymakers in countries with high MDR-TB burden</li> <li>3. Monitoring &amp; evaluation specialists and agencies providing technical assistance</li> </ol>
Objectives	<ol style="list-style-type: none"> <li>1. Learn about enhanced adverse drug reaction monitoring for new TB medicines and novel regimens</li> <li>2. Share experiences, insights, strategies, and results of an effective PV system</li> <li>3. Promote the rational use of TB medicines through strong and proactive pharmacovigilance systems</li> </ol>
Keywords	Patient safety; pharmacovigilance; health systems strengthening
Coordinator(s)	Antonia Kwiecien (USA), Kanjinga Kakanda (USA)
Chair(s)	Ernesto Jaramillo (Switzerland), Norbert Ndjeka (South Africa)
Presentations	<p><b>13:30 - 13:45</b> Pharmacovigilance for TB: what have we learned from HIV and malaria programmes Edward Abwao (Kenya)</p> <p><b>13:50 - 14:05</b> Operational strategy for a holistic approach to monitoring medicines used in South African healthcare programmes Mukesh Dheda (South Africa)</p> <p><b>14:10 - 14:25</b> Cohort event monitoring methodology: data collection, indicators and drug safety profiles Dennis Falzon (Switzerland)</p> <p><b>14:30 - 14:45</b> Strengthening pharmacovigilance systems: improving TB patient safety and reducing the adverse drug reaction burden Antonia Kwiecien (USA)</p> <p><b>14:50 - 15:00</b> Discussion</p>